ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Schwarzkopf In NCCS TV Spot; AACI elects Officers; Nobel Prize In Medicine awarded

October 18, 1996

Campath Improves PFS In B-Cell CLL In Phase III Trial

January 26, 2007

Some Children With Hodgkin’s Disease Can Reduce Or Skip Radiation, Study Finds

October 29, 2004

Complete List of Recommendations by Centers Committee

October 18, 1996

New Drug for Lymphoma Enters Phase II Trial

May 28, 2004

Report Criticizes NIH Grant Review

June 16, 1995